創薬
GPCR構造が創薬にもたらすインパクト
By Miles Congreve, Chris de Graaf, Nigel Swain, Christopher Tate | Apr 6, 2020
サマリー
ヘプタレス社共同創設者のクリストファー・テートとSosei Heptaresの研究者が、最先端のGPCR構造生物学についてのレビューおよび、GPCR薬および臨床試験中の薬剤との相関性についてCellに論文を発表しました。
概要
Structures of 70 unique G protein-coupled receptors (GPCRs) have been determined, with over 370 structures in total bound to different ligands and the receptors in various conformational states. Structure-based drug design has been applied to an increasing number of GPCR targets over the past decade and now a few of these drug candidates have entered clinical trials. Given the length of time required for a drug to reach the market, there are no documented examples of licensed drugs being developed with the aid of a structure, but this is likely to change as current efforts come to fruition.